Jeffrey Fowler, MDThe James Cancer Center
- Gynecologic Oncology
- Gynecologic Cancers
- Ovarian Cancers
- Uterine Cancers
- Minimally Invasive Surgical Procedures
- Endometrial Cancers
- Cervical Cancer
- Vaginal Cancers
- Vulvar Cancers
Make an Appointment
Jeffrey Fowler, MD, is the director of the Division of the Division of Gynecologic Oncology and professor of gynecologic oncology at The Ohio State University Wexner Medical Center. He has extensive expertise in the latest surgical techniques including radical pelvic surgery, pelvic reconstruction and minimally invasive surgery including laparoscopic and robotic surgery. Dr. Fowler has taught these techniques to other surgeons locally, nationally and internationally. As director of the JamesCare for Life program, he also focuses on patient support, education and symptoms relief for patients at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
A native of Traverse City, Mich., Dr. Fowler graduated from Northwestern University Medical School in Chicago. He completed his residency at The Ohio State University College of Medicine. He pursued a fellowship in gynecologic oncology at the UCLA School of Medicine and Cedars-Sinai in Los Angeles. After fellowship, Dr. Fowler joined the faculty of the University of Minnesota Hospital and Clinic as an assistant professor. In 1997, he returned to The Ohio State University College of Medicine as an associate professor of obstetrics and gynecology, and director of the Division of Gynecologic Oncology. In 2001, Dr. Fowler was named the inaugural holder of the John G. Boutselis Chair in Gynecologic Oncology, and in 2002 was promoted to professor.
Dr. Fowler was elected to a three-year term to serve on the Executive Council of the Society of Gynecologic Oncologists starting in 2007. Dr Fowler serves as a board examiner for general obstetrics and gynecology and gynecologic oncology sub-specialty oral exams for the American Board of Obstetrics and Gynecology. He serves on the Board of Governors of the American College of Surgeons. He is on the Gynecologic Oncology Board of the American Board of Obstetrics and Gynecology. He also serves as the chair of the membership committee for the GCF. Dr. Fowler recently completed a two-year term as chief of staff at the OSUCCC – James.
Dr. Fowler has authored or co-authored more than 110 journal articles, and numerous book chapters and abstracts. He is a member of the editorial boards for Gynecologic Oncology and the Journal of Robotic Surgery. His primary research interests have been in advancing the state of the art of surgery in gynecologic oncology including minimally invasive surgery (first laparoscopy and now robotics), radical pelvic surgery and pelvic reconstructive surgery.
Dr. Fowler has received several awards recognizing his excellence in medical student and resident teaching at Ohio State. He has also been recognized for his research presentations. He has been listed among the "Best Doctors in America" for the past 10 years.
Education and Background
Northwestern University Medical School
Ohio State University Wexner Medical Center
OB/GYN / Gynecological Oncology
UCLA Medical Center
- American Board of OB/GYN
- American Board of OB/GYN (Subspecialty: Gynecologic Oncology)
- Department of Obstetrics & Gynecology
- Division of Gynecologic Oncology
I see patients at
JamesCare Gynecologic Oncology at Mill Run
3651 Ridge Mill Drive, Hilliard, Ohio 43026
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 3/28/2017, Dr. Fowler has reported no financial relationships with medical device, research and/or drug companies.